Month: August 2022

Birmingham Women’s and Children’s Hospitals NHS Foundation Trust (BWC) – a founding member of BHP – has announced the appointment of Professor Shakila Thangaratinam to the new post of Research and Development Lead for its Women’s Hospital, and Deputy Director of Research and Development for the Trust. Shakila is BHP’s Academic Lead for Maternal Health and is a Consultant Obstetrician as well as Professor of Maternal and Perinatal Health at the University of Birmingham, where she leads the WHO Collaborating Centre for Global Women’s Health. Here, she explains what her new position will entail and her future ambitions towards improving outcomes for women in Birmingham, the region, and globally.

In my new role, I am keen to facilitate a seamless integration of academia and clinical practice, and nurture the research ambitions of our trainees, midwives, nurses and allied health professionals and Consultant colleagues across various disciplines. Women’s voices will be central to our research development and delivery, and I am particularly keen to minimise the health disparities based on gender, race and ethnicity and socio-economic status. We have a unique strength in caring for women across their life course in our Trust from their birth and childhood, to adolescence, reproductive and post-menopausal age; our research will aim to improve their health throughout this journey.

The new Research and Development Lead role has three clear objectives:

• • To undertake high quality research through improved engagement with women, their families and clinicians, and a clear, achievable, and relevant research strategy
  • To promote capacity-building in research with the tools, skills and career development which are critical to expand and sustain research activities
  • To work closely with patient and public involvement groups such as The Hildas, so that research work addresses the needs of women and families.

“By working closely with the recently established Dame Hilda Network, we hope to bring together clinicians, academics, women and policy makers working towards improving the health of women and their babies in the region, directly addressing the priorities set out by the Women’s Health Strategy nationally.

“In a digital age, we’re well placed to maximise the power of the data in clinical and academic work. We want all women who visit with us to be given the opportunity to be included in our clinical research. Participation in research itself has been shown to improve their outcomes.”

Learn more about BHP’s Maternal Health research

Women around the world should be able to access the best drug treatments that help to delay preterm births and improve outcomes for newborns, suggests new research.

Researchers from BHP founder-member the University of Birmingham worked with colleagues from the World Health Organization to review 122 randomised trials – published between 1966 and 2021, involving 13,697 women and conducted in 39 countries including high, middle and low-income states. The study, published in Cochrane Reviews, has allowed researchers to create a league table of drugs that delay birth, called tocolytics, based on their effectiveness and side effects.

Women benefitted from all preterm delay treatments included in the meta-analysis of studies, although the research team noted that the effectiveness of different drugs was less clear in some of the studies. The team also looked at the side effects of different drugs and combinations, including the likelihood of having to stop treatment.

The team have bought together the evidence on the benefits as well as the harms of these treatments (compared to no treatment or placebo), to arm clinicians and policy makers around with world with the information to decide upon the best treatment for the women in their care in their specific setting.

Dr Amie Wilson, Research Fellow Global Maternal Health at the University of Birmingham said: “The findings show that the benefits of these drugs outweigh any risks associated with unwanted side effects. These treatments are leading to a significant reduction in the number of deadly preterm births, and we now need to further understand the effectiveness of tocolytics for specific groups depending on pregnancy length.

“Our previous research has led to the improvement of guidelines for use of tocolysis drug use to delay preterm birth in the UK. Knowing that this paper helped to inform the forthcoming recommendations of the World Health Organization on the use of tocolytics, we hope that many more women around the globe will have access to these drugs, and have healthier births.”

Dr Victoria Hodgetts Morton, NIHR Clinical Lecturer in Obstetrics at the University of Birmingham and co-author of the paper said: “Preterm birth is the most common reason why a newborn baby may die, and the leading cause of death in children under five years of age.

“Tocolytics aim to delay preterm birth and allow time for the women to receive medicines that can help with baby’s breathing and feeding if born preterm, and medicines that lower the chance of cerebral palsy of the infant. Crucially, a short delay in preterm birth can enable women to reach specialist care.”